At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
Omega-3 fatty acid +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis
In Brief
A clinical study evaluating Omega-3 fatty acid and Placebo for Rheumatoid Arthritis. Completed, enrolled 109 participants across 1 site.
Detailed Summary
The purpose of this study is to see if supplementation of n-3 polyunsaturated fatty acid (PUFA) can be beneficial for the patients with rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
Primary CompletionDec 2011
First PostedJun 2012
TodayJul 2026
First PostedJun 13, 2012
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.1 years ago
Interventions
Omega-3 fatty aciddietary
5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
Placebodietary
5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)